Congress Forces FDA to Evaluate Some ‎‎505(b)(2) Products for Therapeutic Equivalence ‎Listing in ‎Orange Book | Locke Lord LLP
For nearly forty years, the Food and Drug Administration (“FDA”) has required applicants seeking approval of “generic” or “branded generic” drugs under section 505(b)(2) of the Federal...
Source: jdsupra.com